BMS-985521
Phase 1Small molecule
Bristol-Myers SquibbBMS-985521 is one of 31 small molecule programs targeting Drug. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Drug
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Zyvox
PfizerPhase 3
Lamprene
NovartisPhase 3
Deltyba
OtsukaPhase 3
Sirturo
WWim Janssens
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
T-Dxd
Daiichi SankyoPhase 3
Lenvima
EisaiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-985521. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company